Founder Research Benchmark: iTRAQ Quantitative Proteomics & Complement Pathway Inhibition in Inflammatory Arthritis

1. Scientific Context & Challenge

Transparency Note: This record highlights peer-reviewed academic research led by our Founder, Dr. Debasis Sahu (First Author), prior to the incorporation of Ubioquitos Inc., and is presented as a benchmark of our leadership team's primary scientific capabilities rather than a commercial client engagement. The scientific objective was to elucidate the systemic proteome-level mechanism of action of troxerutin in an experimental rat model of adjuvant-induced inflammatory arthritis.

2. Methodological Approach

Dr. Sahu and collaborators across the National Institute of Immunology (NII), ICGEB, JNU, and NYU Grossman School of Medicine performed isobaric tags for relative and absolute quantitation (iTRAQ) mass-spectrometry proteomics, protein-protein interaction network pharmacology, molecular docking, and in vivo histopathology and cytokine profiling.

3. Solution Architecture

Quantitative multi-omic network analysis paired with experimental verification to pinpoint the exact complement cascade effectors modulated during disease remission.

4. Verified Outcome

Published in Frontiers in Cell and Developmental Biology (2022;10:845457; doi:10.3389/fcell.2022.845457; PMID: 35433699; PMCID: PMC9009527), demonstrating that troxerutin downregulates complement component C9 and oxidative/inflammatory effectors in adjuvant-induced arthritis. This primary research underpins the proteomics and systems-pharmacology expertise Dr. Sahu brings to Science Habitat engagements today.

Engagement Specifications

Timeline / Date

Published 31 March 2022 (Academic Study)

Scientific Team

15 Co-Authors (NII, ICGEB, JNU, NYU & Collaborating Institutes)

Scope Classification

Founder Academic Research Benchmark (conducted prior to Ubioquitos Inc. incorporation in June 2022)

Capabilities Applied